Category: Technology
Objective: To report baseline data of the Parkinson’s disease (PD) cohort in the Mobilise-D project.
Background: Mobility is one of the most affected domains in PD, with a highly relevant impact on daily functioning, falls risk and quality of life. There is growing evidence that real-world assessment of mobility using digital technology is feasible and clinically relevant. However, many questions remain unanswered, including how valid are digital mobility outcomes (DMOs) and what is the required length of assessment period to provide valid DMOs, how does mobility change over the course of the disease, and how does mobility relate to common PD symptoms.
Method: In this 2-year longitudinal observational study with 5 visits, 600 persons with PD were included at baseline at 5 European sites (Kiel and Erlangen, Germany; Tel Aviv, Israel; Newcastle, UK; Leuven, Belgium). Participants completed an extensive clinical assessment battery, including (but not limited to) the MDS-UPDRS, Montreal Cognitive Assessment and questionnaires to assess PD-specific aspects, such as freezing of gait, non-motor symptoms and dopaminergic side effects. Mobility was measured using two different wearable devices, one of which was worn continuously on the lower back for 7 days after each visit. Falls diaries were collected to prospectively evaluate the relationship between DMOs and future risk of falls.
Results: The baseline assessment was completed by 600 people with PD. Valid DMO data (i.e., ≥3 days and ≥ 12 hours/day recordings) were obtained from 532 participants. Participants had a wide age range (34-90 years), disease stage (Hoehn&Yahr I-III) and geography (5 countries). No serious adverse events occurred, and 92% reported that being remotely monitored through the wearable device was acceptable to them. About one third reported ≥1 falls in the past 12 months.
Conclusion: The Mobilise-D PD cohort is the largest cohort with longitudinally assessed real-world DMOs currently available. Our baseline analysis shows that the protocol is feasible, that compliance is high, and suggests that relevant questions about PD, mobility, and fall risk can be answered with a granularity not yet achieved in previous studies.
To cite this abstract in AMA style:
W. Maetzler, JM. Hausdorff, H. Gaßner, C. Hansen, A. Mirelman, L. Alcock, P. Brown, C. Becker, J. Garcia-Aymerich, L. Cordova-Rivera, P. Ginis, H. Hunter, I. Neatrour, J. Winkler, J. Kudelka, H. Hildesheim, M. Gordon, P. Goerrissen, B. Caulfield, M. Long, C. Schlenstedt, A. Nieuwboer, L. Rochester, AJ. Yarnall. Baseline Data of the Mobilise-D Parkinson Cohort [abstract]. Mov Disord. 2024; 39 (suppl 1). https://www.mdsabstracts.org/abstract/baseline-data-of-the-mobilise-d-parkinson-cohort/. Accessed May 21, 2025.« Back to 2024 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/baseline-data-of-the-mobilise-d-parkinson-cohort/